COVID-19
On Thursday, Pfizer Chief Executive Officer Albert Bourla who is “not at all” in favor of the U.S. position, stated that the real challenge is manufacturing capacity.
Six months after receiving Emergency Use Authorization from the U.S. FDA for COVID-19 vaccines, Pfizer/BioNTech and Moderna are planning to seek full approval for the preventative medications.
There’s a fair amount of new information coming out about COVID-19 and vaccines. Here’s a roundup of some of the top stories.
While the U.S. had been one of a few rich nations holding out – along with Canada, the European Union and Britain – on some level, Wednesday’s announcement of support for the proposal is not unexpected.
While mix-and-match sounds more like a meal deal at your local fast-food chain, it’s now the colloquial term being used for the approach currently under study in the U.K. for administering two doses of different types of COVID-19 vaccines.
Every week there are numerous scientific studies published. Here’s a look at some of the more interesting ones.
We interviewed Krissy Fuller, a human resources consultant, to learn more about the issue of mandated vaccines from an HR perspective and shared her predictions on what changes she thinks will last after the pandemic.
Newly-published studies suggest currently authorized COVID-19 vaccines may be effective for protecting against new and emerging variants of the novel coronavirus, while booster doses of these vaccines may improve the overall efficiencies of these immunizations at combating these variants.
BioSpace takes a look at data released this week from some of the numerous ongoing clinical studies to advance potential therapies and treatment for disease. Here are some of them.
Patients without diabetes who develop COVID-19 may be at a higher risk of actually developing diabetes following recovery, recent study claims.
PRESS RELEASES